|
Performance of the classifier. Performance of the 13 clusters classifier algorithm re-training and validation on the separate institutional populations using both leave-one-out and multiple 10-fold cross-validations. |
||||||
| Training set (total/events) |
Validation set (total/events) |
Hazard ratio (95%CI) |
Log rank p value |
Distant Metastases Free Survival for low risk group only# |
||
|
|
||||||
| DMFS at 3 years |
DMFS at 5 years |
DMFS at 10 years |
||||
|
|
||||||
| OXFT (99/19) |
KIT/GUYT(156/48) |
2.17 (1.2–3.91) |
<0.00001 |
91% |
87% |
79% |
| KIT (69/20) |
OXFT/GUYT (186/47) |
4.07 (2.23–7.41) |
<0.00001 |
96% |
92% |
88% |
| GUYT (87/28) |
OXFT/KIT (168/39) |
5.93 (3.0–11.75) |
<0.00001 |
93% |
89% |
82% |
| KIT/GUYT (156/48) |
OXFT (99/19) |
14.59 (5.38–39.5) |
<0.00001 |
97% |
94% |
91% |
| OXFT/GUYT (186/47) |
KIT (69/20) |
3.44 (1.36–8.67) |
0.005 |
96% |
92% |
84% |
| OXFT/KIT(168/39) |
GUYT (87/28) |
2.23 (1.05–4.71) |
0.03 |
96% |
92% |
84% |
| Leave-one-out cross validation (255/67)* |
3.86 (2.32–6.41) |
<0.0001 |
94% |
91% |
84% |
|
| Multiple 10-fold cross-validation (255/67) |
3.23 (2.66–3.84) |
<0.0001 |
94% |
90% |
83% |
|
|
# as estimated by Kaplan Meier survival curves. Patients samples obtained from: OXFT: John Radcliffe Hospital, Oxford, UK; KIT Uppsala University hospital, Uppsala, Sweden; GUYT Guys hospital, London, UK. • Reported results. | ||||||
Loi et al. BMC Genomics 2008 9:239 doi:10.1186/1471-2164-9-239 |
||||||